For the prognositc analyses, the UALCAN database was used to study the tumoral DLK2 expression profiles in variable ccRCC patients with different disease stages, tumor grades, metastatic status, cancer subtypes, ages, patient races, and genders. This evidence concerns the gene DLK2 and nonpapillary renal cell carcinoma.